Loading data for TGTX — first visit, this takes a few seconds.

TG Therapeutics, Inc.

NasdaqCM: TGTX · Real-Time Price · USD
55.98
-0.73 (-1.29%)
At close: Sep 04, 2026, 8:00 PM
56.40
+0.74%
After-hours: 7:40 PM

The price, the headline numbers and the latest news, in one place.

TG Therapeutics, Inc. (TGTX) Stock Price, Analysis & Data

No data available

Bid48.41
Market Cap8.57B
Revenue (ttm)800M
Net Income (ttm)441M
1.66
2.74
20.43
18.88
P/B (ttm)13.61
P/S (ttm)10.72
Earnings DateNov 2, 2026
Ask64.12
Volume991,888
Avg. Volume (20D)2,465,591
Open56.33
Previous Close56.71
Day's Range55.56 - 56.70
52-Week Range26.76 - 59.30
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and activ...

Industry Biotechnology
Sector Healthcare
IPO Date May 3, 2010
Employees 399
Stock Exchange NasdaqCM
Ticker Symbol TGTX
Full Company Profile

Financial Performance

In 2025, TG Therapeutics's revenue was 616.29M, an increase of 87.32% compared to the previous year's 329M. Earnings were 447.18M, an increase of 1,812.41%.

Financial Statements

Earnings Surprise

TG Therapeutics has released their quarterly earnings on Aug 3, 2026:
  • Revenue of $240.34M misses estimates by $0, with 70.27% YoY growth.
  • EPS of 0.05 misses estimates by -0.39, with -70.59% YoY decline.
TG Therapeutics, Inc. is scheduled to release its earnings on Nov 2, 2026, before market opens.
Analysts project revenue of ... Upgrade